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Abstract: Glioblastoma (GBM) is the most common, malignant and aggressive brain tumour in
adults. Despite the use of multimodal treatments, involving surgery, followed by concomitant
radiotherapy and chemotherapy, the median survival for patients remains less than 15 months from
diagnosis. Low penetration of drugs across the blood-brain barrier (BBB) is a dose-limiting factor
for systemic GBM therapies, and as a result, post-surgical intracranial drug delivery strategies are
being developed to ensure local delivery of drugs within the brain. Here we describe the effects of
PEGylated poly(lactide)-poly(carbonate)-doxorubicin (DOX) nanoparticles (NPs) on the metabolic
activity of primary cancer cell lines derived from adult patients following neurosurgical resection,
and the commercially available GBM cell line, U87. The results showed that non-drug-loaded NPs
were well tolerated at concentrations of up to 100 µg/mL while tumour cell-killing effects were
observed for the DOX-NPs at the same concentrations. Further experiments evaluated the release
of DOX from polymer-DOX conjugate NPs when incorporated in a thermosensitive in situ gelling
poly(DL-lactic-co-glycolic acid) and poly(ethylene glycol) (PLGA/PEG) matrix paste, in order to
simulate the clinical setting of a locally injected formulation for GBM following surgical tumour
resection. These assays demonstrated drug release from the polymer pro-drugs, when in PLGA/PEG
matrices of two formulations, over clinically relevant time scales. These findings encourage future
in vivo assessment of the potential capability of polymer–drug conjugate NPs to penetrate brain
parenchyma efficaciously, when released from existing interstitial delivery systems.
Keywords: brain tumour; local delivery; polymer pro-drug; nanoparticles; doxorubicin
1. Introduction
Glioblastoma (GBM) is the most common, malignant and aggressive brain tumour in
adults, mainly due to its rapid proliferation and ability to penetrate and diffusely infiltrate
healthy brain parenchyma [1]. Standard of care treatment currently involves a combination
of surgery, radiotherapy and chemotherapy. Yet, despite this multimodal treatment method,
the median survival remains less than 15 months from diagnosis [2]. Local, intracranial
drug delivery has been developed over the last two decades in order to exploit the low
transport of drugs across the BBB, and thus ensure that locally delivered drugs remain
in the brain [3]. As surgery is the usual first step in the treatment of GBM, the rationale
for intracranial drug delivery is based upon a unique treatment window immediately
adjuvant to neurosurgery, in this case by delivering drugs directly to the site of minimal
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volume residual tumour following surgery. In addition, the time just after surgery may be
when tumour heterogeneity is at a minimum, thus facilitating drug treatment with lower
possibilities of resistance. However, more efficacious treatment methods are still necessary
to eradicate residual tumour cells which remain beyond the resection cavity lining after
surgery, as GBM recurrence is almost certain unless these cells are eradicated [4].
Recently, a poly(DL-lactic-co-glycolic acid) and poly(ethylene glycol) (PLGA/PEG)
matrix, consisting ofa thermosensitive in situ gelling PLGA/PEG microparticles, has been
developed as a localised drug delivery system for the treatment of GBM [5,6]. The mi-
croparticles are mixed with saline solutions at room temperature to form a paste, enabling
a surgeon to line the resection cavity site following removal of the tumour. The micropar-
ticles then sinter at 37 ◦C when the microparticles fuse, retaining the cavity lining shape.
Initial studies have demonstrated that chemotherapeutic drugs can be embedded into the
drug delivery matrix and released gradually from the original resection site in the brain,
thus efficaciously targeting the residual infiltrative cells remaining beyond the resection site
with significant overall benefits observed in an orthoptic pre-clinical model [7]. Localised
drug delivery for GBM in this way has major advantages over delivering drugs systemi-
cally, mainly that high therapeutic drug concentrations can potentially be achieved at the
malignant tumour site, whilst avoiding systemic dose-limiting side effects. This method
has been shown to control and sustain the release of chemotherapeutic drug(s) over several
weeks, thus filling the current oncological treatment gap between surgery and radiother-
apy/chemotherapy (typically 3–4 weeks post-surgery).
However, penetration of therapeutic agents from the delivery depot to brain cells
beyond the initial layers at the resection margin still presents a major challenge to effective
treatment. Transport of drugs from the depot takes place largely via passive diffusion,
and this can lead to non-specific uptake of the drugs in healthy cells, as well as the intended
cancer cells, thus limiting further penetration of the drug into underlying cancerous tissue.
In turn, this can result in regrowth of the cancer from beneath the resected layer. There is
accordingly a need to transport the drugs to reach this layer, and the use of a nanoparticulate
carrier is one means by which this might be achieved.
NPs can be internalised by two major endocytosis pathways: phagocytosis and pinocy-
tosis [8]. Pinocytosis accounts for the cellular uptake of smaller NPs (<500 nm) and can
be further distinguished by clathrin-dependent and clathrin-independent pathways [9,10].
NPs can be released from cells via exocytosis, which is distinguished by two main mech-
anisms: regulated exocytosis and constitutive exocytosis. Regulated exocytosis occurs
when the contents of an intracellular vacuole are secreted from the cell in response to a
specific signal, whereas constitutive exocytosis does not require a signal to secrete the
macromolecules [11,12]. Cell internalisation and exocytosis pathways are of importance
when considering the design and application of drug-loaded nanocarriers [13], and re-
peated endocytic and exocytic processes might be exploited by appropriately-designed
NPs to enable ‘hopping’ of the carriers through multiple cell layers in order to enhance
penetration through brain parenchyma. The conjugation of drugs with polymers to form
so called polymeric pro-drugs is a promising approach to overcome drug limitations,
such as solubility and stability, as well as encoding for drug release in specific disease
environments [14,15].
We have recently reported polymer pro-drugs based on a PEGylated poly(lactide)-
poly(carbonate) copolymer (mPEGn-LAm-TBPCp) [16,17], which is based on well-established
chemistries and components already in clinical use. The polymer contains a carbamate
moiety, in the side-chains of the monomer units, which after simple deprotection chem-
istry generates a free primary amine functionality, offering a simple conjugation point
for drugs to be linked to the polymer backbone [16,17]. The polymer contains primary
amine functionality in the side-chains of one of the monomer units, offering a simple
conjugation point for drugs to be linked to the polymer backbone. We selected DOX as
the drug candidate of first choice, due its use in multiple studies in vitro [18], in vivo [19]
and human clinical trials [20,21], and its relevance in the treatment of GBM. Systemic injec-
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tion of free DOX, however, does not lead to high concentrations crossing the blood–brain
barrier (BBB) [22], and so many researchers have utilised DOX-loaded NPs as a means
to traverse the BBB [23–25]. For our studies, we wanted to evaluate whether localised
delivery of polymer-DOX pro-drug NPs from the PEG-PLGA in situ gelling paste could
avoid the issues of BBB transport while also allowing for transcytotic ‘hopping’ [26] of
the NPs beyond the resection layer. In this way, we aimed to enhance the delivered dose,
while also increasing the potential targeting of DOX to cancerous cells by conjugating it to
the polymer by a urea linker, which could exploit the higher urease activity reported in
some cancer cells. We further aimed to address the increased intrinsic resistance of GBM to
chemotherapeutic drugs, caused by the heterogeneity of the tumour micro-environment
and subsequent genetic and epigenetic variation in tumour subclones as a result of vari-
able selective pressures. Most commercial GBM cell lines have been historically derived
from the MRI contrast-enhanced core region of tumours, which does not allow a realistic,
phenotypically accurate representation of the infiltrative cells which remain after surgery
and ultimately result in the inevitable recurrence of GBM [27]. Significantly, residual cells
at the tumour margin are responsible for the ~85% of GBMs that relapse locally (typically
within 2 cm3 of the infiltrative margin) after maximal safe surgical resection followed by
the standard combination protocol of oral temozolomide and radiotherapy [28]. Thus,
we wanted to evaluate whether the polymer pro-drugs designed to transport and release
DOX might be more active against invasive patient-derived GBM cells than the standard
GBM cell lines, as this would be an important step for developing more clinically-relevant
therapies for this pathology [29]. We therefore utilised cell lines derived from the infiltrative
margin of adult patients, defined by areas of minimal fluorescence during 5-aminolevulinic
acid (5-ALA) fluorescence-guided neurosurgical resection, at the Queen’s Medical Centre,
University of Nottingham [7,29]. We have thus studied the effects of polymeric pro-drug
NPs on the metabolic activity of these primary cell lines and the widely-used commercial
GBM cell line, U87. In addition, we have studied the release profile of the DOX-loaded
NPs from the PLGA/PEG matrix and DOX release from NPs as the first steps towards
establishing the dual polymer pro-drug/depot delivery system for GBM therapy.
2. Materials and Methods
All materials were used as obtained unless otherwise stated. Dulbecco’s Phosphate-
Buffered Saline (PBS; modified without calcium chloride and magnesium chloride; sterile-
filtered), Dimethyl Sulfoxide (DMSO, >99.7%; sterile-filtered) and sterile water (sterile-
filtered) were purchased from Sigma Life Science (St. Louis, MO, USA). Astrocyte Medium
(AM; sterile filtered), Poly-L-Lysine (1 mg/mL; sterile filtered), Trypsin/EDTA solution
(T/E; 0.25%; sterile-filtered) and Trypsin Neutralisation Solution (TNS; sterile filtered)
were purchased from ScienCell Research Laboratories (Carlsbad, CA, USA). Hank’s Bal-
anced Salt Solution (HBSS; sterile-filtered), Dulbecco’s Phosphate-Buffered Saline (DPBS;
supplemented with calcium chloride and magnesium chloride), Dulbecco’s Modified Ea-
gle Medium (DMEM; supplemented with 1 g/L D-glucose L-glutamine and pyruvate),
phenol red-free DMEM (with 4500 mg/L glucose and sodium bicarbonate and without
L-glutamine, sodium pyruvate and phenol red) and FluoroBrite DMEM were purchased
from GibcoTM by ThermoFisher Scientific (Waltham, MA, USA). PrestoBlueTM Cell Viability
Reagent and Hoechst 33342 were purchased from InvitrogenTM by ThermoFisher Scientific.
HyCloneTM Bovine Growth Serum (FBS; GE Healthcare) was purchased from Fisher Scien-
tific by ThermoFisher. Acetone (>99.8%) was purchased from Fisher Chemical (Hampton,
NH, USA). Dimethyl Sulfoxide (DMSO) was purchased from Honeywell (Charlotte, NC,
USA). Poly(ethylene glycol) (PEG; Mn = 400 Da) was purchased from Aldrich Chemistry.
Poly(lactic-co-glycolic acid) Resomer® (PDLLGA; Select 85:15 DLG 4CA; technical grade)
was purchased from Evonik (Essen, Germany). Doxorubicin (hydrochloride) (DOX.HCl)
was purchased from Cayman Chemical company (Ann Arbor, MI, USA). Synthesis of
all the polymers was via ring opening of lactide and a t-butyloxycarbamoyl-protected
cyclic carbonate monomer (TBPC) derived from serinol by methoxypoly(ethyleneglycol)s
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to generate polymers abbreviated as mPEG5000-(LA)n-(TBPC)y, followed by Cy5-labelling
and DOX coupling to produce the final pro-drug platforms were performed following
previously reported protocols [16,17].
2.1. Nanoparticle Stability Studies
NPs were formed using a ‘nanoprecipitation’ method to generate kinetically trapped,
‘micellar-like’ NPs. In these experiments, the polymers (10 mg) were dissolved in acetone
(1 mL), and the polymeric dispersion was added dropwise to deionised water (10 mL,
final concentration of 1 mg/mL) under constant stirring at 550 rpm. The polymers rapidly
formed NP suspensions as solvent exchange between water and acetone led to aggre-
gation of the hydrophobic poly(lactide-co-carbonate) blocks. The final suspension was
subsequently dialysed in a 3.5 kDa molecular weight cut-off dialysis tubing against PBS
overnight in order for complete exchange between water and PBS. The resultant sizes of
the NPs were derived via DLS measurements following filtration using a 0.22 µm filter.
Control NPs (final conc. 500 µg/mL) were stored at 4 ◦C, whilst another set were mixed 1:1
with DMEM (final conc. 500 µg/mL) and stored at 37 ◦C, to provide a cell culture medium
environment. The particle sizes were determined by DLS at time points 1, 4, 24, 48 and
168 h using a Zetasizer Nano ZS (Malvern Instruments Ltd., Malvern, UK). Measurements
were taken in triplicate of NPs suspensions at 500 µg/mL and used to calculate mean
intensity particle size distributions.
2.2. Cell Culture
The U87 GBM cell line was obtained from ATCC and cultured within a passage
window of 13 passages. U87 cells were cultured in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% (v/v) Foetal Bovine Serum (FBS) at 37 ◦C in a humidified
incubator with 5% CO2. GIN-8 (Glioma INvasive margin cells) were isolated from medial
front invasive margin (54 y female, wild-type IDH (primary GBM), intact ATRX, 0% MGMT
promoter methylation, 90% resection plus Gliadel wafers; treatment 60Gy radiotherapy,
concurrent and adjuvant temozolomide; patient died 5 months after surgery), GIN-28 were
isolated from 5-ALA fluorescence-positive invasive margin (71 y male, wild-type IDH
(primary GBM), intact ATRX, 0% MGMT promoter methylation 99% resection; no adjuvant
therapy (patient choice); died 3 months after surgery) [29] and GIN-31 were isolated
from 5-ALA fluorescence-positive invasive margin (wild-type IDH (primary GBM), intact
ATRX, 0% MGMT promoter methylation, 100% resection; treatment 60Gy radiotherapy,
concurrent and adjuvant temozolomide; patient died 16.1 months after surgery) by our
laboratory, and were used at passages of 24–50, 26–41 and 28–55, respectively. GIN cell lines
were cultured in Dulbecco’s Modified Eagle Medium (DMEM; Sigma-Aldrich, St. Louis,
MO, USA) supplemented with 10% FBS, 1 g/L glucose and 2 mM L-glutamine (Sigma-
Aldrich) at 37 ◦C with 5% CO2. The optimisation of seeding densities for the GIN lines
for assaying was based on their proliferation and is shown in Supplementary Figure S1.
A primary human astrocyte cell line was used as a comparator of healthy brain cells.
This was obtained from ScienCell Research Laboratories (catalogue #1800) and cultured
between passage 3 and 10. Primary human astrocytes were cultured in Astrocyte Medium
(AM) supplemented with 2% FBS (v/v), 1% penicillin-streptomycin (v/v) and 1% Astrocyte
Growth Medium (v/v) at 37 ◦C in a humidified incubator with 5% CO2. Cells were cultured
in flasks previously coated with poly-l-lysine (150 µL; 10 mg/mL) and sterile water (10 mL;
final concentration 2 µg/cm2) for a minimum of one hour to promote adhesion of the cells.
The 9L rat glioma cell line was received as a gift from Prof. Henry Brem and Dr. Betty Tyler
from Johns Hopkins University. The cell line was cultured in DMEM supplemented with
10% FBS, 1 g/L glucose and 2 mM L-glutamine at 37 ◦C with 5% CO2.
2.3. Cytotoxicity Experiments
The PrestoBlue™ Cell Viability assay was performed to assess the metabolic activity of
cell lines used following exposure to blank NPs, doxorubicin and doxorubicin-NPs. All cells
Pharmaceutics 2021, 13, 208 5 of 17
were seeded at a density of 5 × 103 cells per well, with the exception of 9L and GIN-31
cells which were seeded with 3 × 103 cells per well, in 96 well plates and cultured for 24 h
prior to treatment. Cells were exposed to treatments for 72 h and applied in 100 µL DMEM
containing 10% (v/v) FBS. DMSO (100%) was used for a cell death (positive) control and a
vehicle control (100% DMEM) used as a negative control. Following exposure, treatments
were removed, and the cells were subsequently washed twice with warm Hank’s Balanced
Salt Solution (HBSS). A volume of 110 µL 10% (v/v) PrestoBlue™ reagent diluted in HBSS
was applied per well for 45 min. The resulting fluorescence was measured at 544/590 nm
(λex./λem.) on a BMG Labtech FLUOstar Omega microplate reader. Relative metabolic
activity was calculated by setting normalised values from the negative control as 100% and
positive control as 0% metabolic activity.
2.4. Fluorescent Live-Cell Microscopy
To investigate cellular uptake, live-cell fluorescence microscopy was used to image
GIN8, GIN28 and U87 cells. NPs for uptake experiments were prepared as previously
described but were formulated as 10% wt/wt of mPEG5000-(LA)50-(TBPC)50-Cy5 (P2-Cy5)
and 90% wt/wt mPEG5000-(LA)50-(TBPC)50 (P2) and diluted to a final concentration of
50 µg/mL in 10% (v/v) FBS containing DMEM (no phenol red). GIN8, GIN28 and U87 cells
were seeded in CellView™ 35 mm diameter glass-bottom cell culture dishes at a density
of 2.5 × 105 cells per dish and cultured for 24 h. Cy5-NPs (50 µg/mL) were incubated
with cells for 0.5, 2 and 4 h at 37 ◦C with 5% CO2. Following exposure, NP solutions
were removed and cells washed three times with ice-cold PBS. Cells were then stained
with 10 µg/mL Hoechst 33342 (Thermo-Fisher) or 10 µg/mL Hoechst 33342 and 50 nM
Lysotracker green DND-26 (Thermo-Fisher) applied in Hank’s Balanced Salt Solution
(HBSS) for 30 min. Staining solution was removed and cells washed twice with PBS.
FluoroBrite DMEM was added to wells and cells were imaged on an inverted Nikon Eclipse
TE 300 fluorescent microscope on DAPI, FITC and Cy5 filters. Images were processed
using ImageJ software (1.52f) and the Coloc 2 plug in was used for calculation of Pearson’s
correlation coefficient for co-localisation studies.
2.5. Fluorometric-Based Uptake Assessment
GIN8, GIN28 and U87 cells were plated at 5.8 × 104 cells per well in 24 well plates.
Following a 24 h culture period, culture medium was removed and Cy5-NPs were applied
in phenol red free medium containing 10% (v/v) FBS. The time dependence of cell uptake
was assessed with 50 µg/mL solutions of nanoparticles and at time points of 5, 15, 30, 60,
120, 180, and 240 min. Following exposure, NP solutions were removed and cells washed
three times with ice-cold PBS. Cells were then permeabilised with 1% (v/v) Triton X-100
solution applied in PBS for 10 min at 37 ◦C. Permeabilised cells were thereafter pelleted by
centrifugation and nanoparticles quantified by fluorescent measurement at 640/680 nm
(λex./λem.) using a Tecan Spark 10M plate reader. Quantification of nanoparticle uptake
was achieved via calibration curves of known nanoparticle concentrations diluted in 1%
(v/v) Triton X-100 in PBS solution. Values were normalised to viable cell number per well
determined by the trypan blue exclusion test and cell counting on a haemocytometer.
2.6. Preparation of PLGA/PEG Matrix
The PLGA/PEG paste was prepared as described previously [30,31]. In brief, thermosen-
sitive microparticles were fabricated from blends of 53 kDa PDLLGA (85:15 DLG 4CA) and
PEG. A mixture of 93.5:6.5% PLGA:PEG (w/v) was blended at 80–90 ◦C on a hotplate.
The melted PLGA and PEG were mixed by hand using a polytetrafluoroethylene (PTFE)-
coated spatula and the mixture cooled to room temperature. Polymer blend sheets were
then ground into particles in a bench-top mill (Krups Mill F203) and the particles were
sieved to obtain the 100–200 µm particle size fraction.
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2.7. Release Studies
2.7.1. DOX Release from DOX-NPs
Polymer-DOX conjugates were formulated by nanoprecipitation to form DOX-NPs of
size 67 nm and at a concentration of 2 mg/mL in PBS, as previously described, and DOX
release from DOX-NPs was measured. Following dialysis against PBS, the resultant NPs
(500 µL) were pipetted into a Slide-A-Lyser® MINI Dialysis device with a 3.5 kDa molecular
weight cut off, with 14 mL PBS in the Eppendorf below. At set time points (t = 0.02, 0.04,
0.08, 0.17, 0.25, 1, 2, 3, 6, 7, 28 and 44 days), the entire 14 mL PBS sample was removed
and replaced with fresh PBS. The removed PBS sample was freeze-dried and resuspended
in DMSO (5 mL), sonicated for 10 min and centrifuged for a further 10 min. The DOX
present in the resultant supernatant sample (2 mL) was analysed by fluorescence on a
Varian CaryEclipse Fluorescent Spectrometer. The sample was read on the slow scan mode,
450/510–640 nm (λex./λem.) at 900 V, with excitation split set at 5 nm and emission split
set at 10 nm.
2.7.2. DOX-NP Release from PLGA/PEG Paste
DOX-NPs were formulated as previously described (5 mg/mL). When forming the
PLGA/PEG paste, the DOX-NP solution replaced the PBS to form DOX-NP-loaded-
PLGA/PEG paste. PLGA/PEG microparticles (636 mg; 100–200 µm) were mixed with
509 µL DOX-NPs (dialysed overnight against PBS; final conc. 2.65 mg/mL) and were split
evenly six ways (106 mg PLGA/PEG; 84.83 µL DOX-NP), approximately maintaining the
previously optimised 1:0.8 (polymer:saline) ratio required for a glass transition temperature
of 37 ◦C [6]. Three formulations were packed tightly into cylindrical moulds (6 × 6 × 2 mm;
l × w × d) and the remaining three were pasted lightly into a weighing boat, producing
a thin layer to mimic more closely how the polymer will be applied to a resection cavity
in vivo. The PLGA/PEG matrices were sintered overnight at 37 ◦C. Release was assessed
through placing the sintered PLGA/PEG matrices into a scintillation vial containing 5 mL
PBS. At set time points (t = 0.02, 0.04, 0.08, 0.17, 1, 2, 5, 6, 7, 28, 43 and 63 days), the entire
5 mL PBS sample was removed and replaced with fresh PBS. The PBS sample was freeze
dried, resuspended in DMSO (5 mL), sonicated for 10 min before centrifuging for a further
10 min. The DOX present in the resultant supernatant sample (2 mL) was analysed by
fluorescence spectroscopy using a Varian CaryEclipse Fluorescent Spectrometer and was,
by proxy, attributed to DOX-NP release from PLGA/PEG paste. The sample was read on
the slow scan mode, 450/510–640 nm (λex./λem.) at 900 V, with excitation split set at 5 nm
and emission split set at 10 nm.
2.8. Statistical Analysis
Except where stated otherwise, in the individual experimental methods sections
above, each in vitro experiment was performed independently three times in triplicate.
Statistical significance was accepted at a level of p < 0.05 (* p < 0.05; ** p < 0.01; *** p < 0.001;
**** p < 0.0001). GraphPad Prism software (v8.1) was used for statistical analysis and
IC50 values calculated by fitting the data to a non-linear dose–response curve with a
variable slope.
3. Results
The polymers used in this study are shown in Scheme 1 and their key attributes in
Table 1.
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Table 1. Chemical characterisation of the PEGylated copolymers, nature of PEG blocks and number of polymer arms.
Polymer PEG Length (Da) Final Polymer Arms Mn (NMR) Mn 1 (GPC) Ð
P1. mPEG2000-(LA)50-(TBPC)50 2000 1 20,500 20,400 1.3
P2. mPEG5000-(LA)50-(TBPC)50 5000 1 23,000 24,000 1.2
P3. PEG4000-(LA)50-(TBPC)50 4000 2 21,000 20,000 1.1
P4. PEG1014-(LA)50-(TBPC)50 1014 3 19,000 16,400 1.2
P5. PEG797-(LA)50-(TBPC)50 797 4 21,000 16,300 1.2
1 Compared to PMMA standards, Ð: dispersity.
The polymers were all synthesised by ring-opening polymerisation, as described
previously [16,17], and were characterised by NMR spectroscopy and gel permeation
chromatography (GPC), as shown in Table 1.
3.1. Nanoparticle Stability
Initial stability studies were carried out in order to mimic two common environments
for nanoformulations, in particular, “control NPs” were kept at 4 ◦C to replicate storage
of NPs in standard cool-chain conditions and the “experimental NPs” were kept at 37 ◦C
in DMEM, replicating the physiological conditions for future in vitro work. A DLS-based
assay was chosen as the screening technique due to the fast response time and ease of
detection of aggregation within each sample [32].
As can be observed in Figure 1, no substantial changes in size were observed for the
NPs kept at 4 ◦C, confirming primary colloidal stability in these conditions, except for the
P4 formulation whereby a slight shift to a larger size was observed over time, indicating
aggregation of the NPs. When incubated at 37 ◦C in DMEM cell culture medium, changes
in the DLS plots were apparent after the 24 h time points for all the formulations, with a
broadening of the peaks and a shift to larger size ranges, suggesting the particles were
aggregating before collapsing. For particles P1, P2, P3 and P5, the DLS traces continued
to broaden until the one-week time point. NPs produced from P4 proved to be much
less stable than the other formulations, and aggregation of the NPs occurred within a 1 h
timeframe. Since standard internalisation assays in cell culture are typically conducted
over time periods of several hours, these initial assays indicated that all the NPs except
P4 were sufficiently stable for initial cell culture experiments over standard time ranges,
and that the formulations were also storage stable.
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Figure 1. Dynamic Light Scattering ( LS) plots for NP formulations of P1–P5 under cool-chain storage (‘control’) conditions
(PBS at 4 ◦C; top row) and in cell culture medium (DMEM at 37 ◦C; bottom row) after 0, 1, 24, 48 h and 1 week of incubation.
No significant cha ges i particle size were observed for the NPs in control conditions r for P1, P2, P3 and P5 in DMEM prior
to the 24 h time points. P1, mPEG2000-(LA)50-(TBPC)50; P2, mPEG5000-(LA)50-(TBPC)50; P3, mPEG4000-(LA)50-(TBPC)50;
P4, mPEG1014-(LA)50-(TBPC)50; P5, mPEG797-(LA)50-(TBPC)50.
3.2. Cytocompatability
Initial NP cytocompatibility screening was conducted using the PrestoBlue™ assay in
the standard U87 glioblastoma-derived cell line. As can be seen from Figure 2, increasing
concentrations of each of the polymeric NP formulations tested did not markedly alter
metabolic activity compared to the negative control. No observed reduction in cellular
metabolic activity was observed after 72 h, indicating that the polymer ‘platform’ of PEG-
poly(lactide)-co-poly(carbonate) was well tolerated by the brain tumour cells.
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Pharmaceutics 2021, 13, 208 9 of 17
From the initial set of materials, we selected P2 for further in vitro studies, as these
polymers formed NPs at a low critical aggregation concentration (CAC = 8.5 µg/mL, exhib-
ited zeta potentials of −23.5 ± 4.5 mV (Supplementary Table S1), suggesting good colloidal
stability, and the particle sizes of the as-formed NPs were the equal lowest amongst the
set (47 nm), which we anticipated would enhance tissue penetration. The P4 and P5 poly-
mers were omitted due to a lack of stability in storage conditions, while P1 and P3 were
formed with PEG chains of reduced length (Mn = 2000, 4000) compared to P2 (Mn = 5000).
It has been reported that increased PEGylation at a surface also aids penetration through
brain tissue [33,34], providing further support for P2 as the lead formulation in this con-
text. Accordingly, the P2 polymer was used in further cytocompatibility experiments,
and was further derivatised for subsequent experiments by partial side-chain deprotection
and coupling of doxorubicin via a urea linker, to form polymer P6-(mPEG5000-(LA)50-
(TBPC)50−x-DOXx).
3.3. Lead Nanoparticle Cytocombability Screening
To demonstrate cytocompatibility of the lead NP candidate in more translationally
relevant cell lines, the effects of the polymers on metabolic activity were assessed in a non-
tumourigenic, primary human astrocyte line (Figure 3A), 9L rat glioma cells (used widely
to generate immune competent glioma allografts) (Figure 3B), and a panel of primary cell
lines derived from the invasive margin of GBM patients (Figure 3C–E). These latter cell lines
(GIN-8, GIN-28 and GIN-31) better represent the cancerous cells remaining in the brain
following maximal safe surgical resection, compared to classical cell lines derived from
the tumour core. In these cell lines, P2 demonstrated safe application at all concentrations
tested (≤1000 µg/mL) (Figure 3C,D), with the exception of the GIN-8 cell line in which
cytotoxicity was observed at 1000 µg/mL (Figure 3E).
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3.4. Assays to Evaluate Cellular Internalisation of NPs
In order to deliver any drug cargo, efficient internalisation of NPs is critical, and thus
to investigate the uptake of the P2 formulation, a fluorophore (Cy5) was conjugated to the
P2 polymer prior to NP formation (see Materials and Methods). These Cy5-NPs were then
applied to GIN8, GIN28 and U87 cells for 0.5, 2 and 4 h and the cells imaged via live-cell
fluorescence microscopy (Figure 4). The cellular imaging demonstrates that NP uptake
appeared time dependent, with the least Cy5 signal being observed at 0.5 h relative to the
later time points. Furthermore, from microscopy it can observed that the Cy5-NP signal
appears to be localised to the cytoplasm with an absence of signal in the cell nuclei at all
time points (Figure 4).




Figure 4. Uptake characteristics of Cy5-NP P2 in GBM cells. (A–C) Fluorescent micrographs of 
nanoparticle internalisation in (A) U87, (B) GIN28 and (C) GIN8 cells. Cells were incubated with 
nanoparticle solution at concentration of 50 µg/mL for 0.5, 2 and 4 h. (i, ii, iii) Enlarged areas high-
lighted by white boxes. Scale bar = 20 µm. Images are representative of three independent experi-
ments. 
Fig re 4. Uptake characteristics of Cy5-NP P2 in GBM cells. (A–C) Fluorescent micrographs of
nanoparticle internalisation in (A) U87, (B) GIN28 and (C) GIN8 cells. Cells were incubated with
nanoparticle solution at concentration of 50 µg/mL for 0.5, 2 and 4 h. (i, ii, iii) Enlarged areas highlighted
by white boxes. Scale bar = 20 µm. Images are representative of three independent experiments.
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To investigate the potential differences in the rate of NP uptake in different GBM cell
lines, a quantitative kinetic uptake experiment was performed (Figure 5). Analysis reveals
that the highest levels of NP uptake were experienced by GIN8 cells, followed by GIN28
cells and with U87 demonstrating the lowest uptake levels. It can be noted that the fastest
rates of uptake for all cell lines tested were demonstrated in the first 5–60 min, followed by
subsequent rate decrease in the time points thereafter (Figure 5).




Figure 5. Assessment of NP-Cy5 uptake kinetics in GIN8, GIN28 and U87 cell lines using the fluo-
rometric method. Cy5-NP P2 was applied at 50 µg/mL in 10% (v/v) containing DMEM. Data pre-
sented as the mean ± S.D (n = 3). 
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Images were processed on Image J software. Cy5 signal of NP-Cy5 was false coloured to red to aid 
in visualisation of co-localisation with green lysosomal signal. Merged images include NP-Cy5 
signal, lysosome stain and Hoechst 33342 staining of nuclei. Scale bar = 20 µm. 
As apparent in Figure 7, a burst release of DOX from the NPs occurred over the first 
6 h (Figure 7B(BI)), with over 60% of DOX released within the first 24 h. After this time 
point, steady state release was observed, with just over 80% of the drug cumulatively re-
leased over the following 44 days (Figure 7B). This burst release was surprising, consid-
ering the expected stability of the urea bond conjugating the DOX to the polymer back-
bone [38]. However, it has been reported that a urea bond can be weakened when a large, 
sterically hindered substituent group constitutes the secondary amine [39,40], and in this 
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metric method. Cy5-NP P2 was applied at 50 µg/ i ( v) containing DMEM. D ta presented
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Finally, to investigate whether NP-Cy5 P2 localised in lysosomal compartments fol-
lowing uptake, Lysotracker Green DND-26, a lysosomal marker was used in co-localisation
studies (Figure 6). Following a 4 h incubation with NPs, co-localisation of NP-Cy5 (red)
and Lysotracker green (green) was observed in GIN8, GIN28 and U87 cells, indicating
the internalisation of NP-Cy5 P2 was occurring via endocytosis and trafficked to lyso-
somes. Such intracellular trafficking following endocytosis has been widely reported for
polymeric NPs [35,36] and is in agreement with previous studies on our NPs in different
cell lines [16,37].
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Figure 6. Co-localisation studies in GBM cells. Cells were treated with 50 µg/mL NP-Cy5 for 4 h.
Image were pr e sed on Image J ftware. Cy5 sign l of NP-Cy5 was false coloured to red to aid in
visualisation of co-localisation with green lysosomal signal. Merged images include NP-Cy5 signal,
lysosome stain and Hoechst 33342 staining of nuclei. S ale bar = 20 µm.
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3.5. Drug Release Studies
Measurements of DOX concentration following incubation in PBS of the P6 polymer
DOX-NP formulation (P6-mPEG5000-(LA)50-(TBPC)50−x-DOXx), and from the P6 formu-
lation when in the PLGA-PEG microparticulate matrix, were carried out to establish the
timeframe of drug release. The PLGA-PEG matrix was prepared in two forms to mimic
possible clinical settings. In the first format, a paste was prepared using pre-formed mi-
croparticles blended with P6, to represent the formulation being pasted onto the cavity
walls of the brain after surgery. In the second form, sintered mixtures of PLGA-PEG and
P6 were formed into moulds to mimic brain cavity shaped implants.
As apparent in Figure 7, a burst release of DOX from the NPs occurred over the first 6 h
(Figure 7B(BI)), with over 60% of DOX released within the first 24 h. After this time point,
steady state release was observed, with just over 80% of the drug cumulatively released
over the following 44 days (Figure 7B). This burst release was surprising, considering the
expected stability of the urea bond conjugating the DOX to the polymer backbone [38].
However, it has been reported that a urea bond can be weakened when a large, sterically
hindered substituent group constitutes the secondary amine [39,40], and in this case
the polymeric backbone may have acted as an appropriately large, sterically hindered
moiety. Furthermore, the structures of the kinetically trapped NPs may have influenced
the release rate of DOX, as the ingress of aqueous fluids to hydrolyse the polymer-DOX
link, is highly dependent on chain packing in the NP. Polymer chains near the surface
of the NP would be accessible to the aqueous buffer, leading to more rapid cleavage of
urea links, whilst DOX-conjugates trapped near the centre of the particle would be less
hydrated, slower to react and thus release the DOX more slowly. In addition, local pH
values might vary considerably at different ‘depths’ in the kinetically trapped NP interior,
leading to different rates of urea hydrolysis as poly(lactide) bonds also hydrolysed in the
NP. Nevertheless, the release profiles obtained indicated that sufficient DOX was released
from the NPs within the first 24 h (8.75 ± 1 µg) to achieve concentrations appropriate for
in vitro cytotoxicity assessment. In terms of the different formulations, the release from
the “paste-like” PLGA/PEG matrix was faster than that from the tightly packed mould.
Again, a burst release of the drug-conjugated NPs from the microparticulate matrix paste
was observed during the first 8 h. This likely arose because the DOX-NPs remained on
the surface of the matrix during the mixing process with the PLGA/PEG microparticles.
A much less rapid release profile was obtained from the moulds during the first 24 h,
indicating that there were fewer NPs hydrolysing at the surface compared to those in the
paste, and the overall level of drug liberated from the moulds was lower than that from the
paste. This was probably a consequence of reduced ingress of moisture in the more densely
packed matrix. The cumulative release of DOX from the moulds was also less, reaching less
than 40% of total drug loaded after two months, whereas almost 70% of DOX was released
from the DOX-NPs in the paste over the same time period. For potential formulations used
in post-surgery GBM application, DOX release from NPs would be required to occur later
than DOX-NP transport from the PLGA/PEG matrix, in order that drug release occurs
after NPs have penetrated the brain parenchyma beyond the infiltrative tumour margin,
thus potentially targeting distal residual disease cells which persist after surgical resection.
These data overall indicated that it was possible to sustain drug release over clinically
relevant time points, as well as to effect control over burst vs. sustained release.
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Figure 7. ( ) P6- PE -(L )50-(TBP )50−x-DOXx formulation, showing average size obtained
for each of the in vitro experiments carried out in this f rk. (B(BI)). Cumulative% and µg of
DOX rel -loaded NPs over 4 days (B) and 24 h (BI). (C,D). Rel ase was carried
out i i e points repres nt one independent repeat (n = 3) with error bars showing the mean ±
one SD. Cumulative% and µg of DOX-NP release from the PLGA/PEG microparticulate mat ix over
63 days (C) and 24 h (D). Release was carried out in PBS. Time points represent one independent
repeat (n = 3) with error bars showing mean ± one SD.
3.6. Effects of DOX-Loaded Nanoparticles in Glioblastoma Cells
The potencies of free DOX and DOX-NPs were assessed in U87 cells and in three
primary GBM cell lines (GIN-8, GIN-28 and GIN-31) (Figure 8). In both treatment conditions
(DOX and DOX-NP), it was observed that the commercially available U87 cell line was
the most treatment-sensitive GBM line tested. The GIN-28 cells were determined to be the
most susceptible primary patient-derived cell lines to DOX-based treatments, followed
by GIN-8 and GIN-31, which displayed similar levels of sensitivity to DOX and DOX-NP
(Figure 8). The variation in potency observed between the patient-derived lines is likely
due to the variability between patients (intertumour heterogeneity) and highlights the
importance of studying multiple cell lines. Furthermore, the relatively lower sensitivity
to DOX in GIN lines likely reflects the lower proliferative rate of primary patient-derived
cells lines, relative to the in vitro-adapted U87 line. IC50 in GIN lines are therefore a more
physiologically accurate test bed to evaluate chemotherapy response.
The experiments demonstrated that the DOX-NPs were less cytotoxic than free DOX
in all cell lines tested, with IC50 values 70-fold, 34-fold, 50-fold and 20-fold higher in U87,
GIN-8, GIN-28 and GIN-31 cells, respectively (Figure 8E). Interestingly, the decreases in po-
tency experienced by the pro-drug formulation in the different cell lines (Figure 8E) reflect
the rankings of the internalisation levels in the tested cell lines (Figure 5). For example,
U87 cells demonstrated the lowest levels of internalisation and subsequently the largest
decrease in DOX vs DOX-NP potency.
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potential and colloidal stability. These studies included investigating the metabolic activ-
ity of a primary human astrocyte cell line and a panel of primary GBM cell lines when 
treated with both P2 NPs and a conjugate of P2 with DOX, termed P6. Control P2 NPs 
exhibited no adverse effects at concentrations of up to 100 µg/mL in the astrocyte line and 
in each of the primary GBM cell lines, whereas P6 DOX-NPs were cytotoxic for U87 cells 
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Figure 8. Potency of DOX and DOX-NPs in U87 (A), GIN-8 (B), GIN-28 (C), and GIN-31 (D) cell
lines. Treatments were applied in DMEM containing 10% FBS and exposed for 72 h. Potency was
determined via assessment of cellular metabolic activity using the PrestoBlue assay. Data presented
as the mean ± S.D from four independent repeats. IC50 values (mean ± S.E.M) were calculated and
are shown in the table (E).
While the decrease in drug potency is not unexpected over the time periods of 2D cell
cultur assays, as internalisation of free drug is more rapid than endocytosis and pro-drug
activation f om polymer chain, in previous studies hese polymer DOX-NPs achieved
greater than or equ l potency to free DOX in breast, lung, skin and intesti al tumour
cells [16,37]. We suggest ther fore that the sp cific GBM cells studied, either internalised
th NPs less efficiently than the fr e dr g over the time p riods of the assay and/or that
the urea linker in the DOX polymer conjugates was more stable in these li s than in
those assayed previously.
Nevertheless, the demonstration of appropriate cytotoxicity in patient-derived GBM
cells with the DOX-NPs, together with their successful incorporation in the PLGA/PEG
microparticulate local delivery matrix (Figure 8) and s ccessful release of DOX, highlights
the potential of this hybrid system for future development in GBM pre-clinical odels.
4. Conclusions
We have investigated the effects of a range of polymer NPs in GBM cell lines from the
therapy relevant infiltrative margin and found that all polymeric formulations were well
tolerated in the absence of a drug payload. A single polymer formulation (P2) was selected
for further study based on an expected favourable profile of particle size, zeta potential
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and colloidal stability. These studies included investigating the metabolic activity of a
primary human astrocyte cell line and a panel of primary GBM cell lines when treated
with both P2 NPs and a conjugate of P2 with DOX, termed P6. Control P2 NPs exhibited
no adverse effects at concentrations of up to 100 µg/mL in the astrocyte line and in each
of the primary GBM cell lines, whereas P6 DOX-NPs were cytotoxic for U87 cells and the
three primary GBM cell lines investigated. Drug release studies were carried out using
P6 DOX-NPs in buffer and P6 DOX-NPs loaded into PLGA/PEG paste and moulded
monoliths. Data from these experiments indicated that sufficient DOX was released from
the NPs to achieve a cytotoxic dose in vitro. Furthermore, a burst release of the drug from
the P6 DOX-NPs in the microparticulate paste matrix (mimicking the intended surgical
application) was observed during the first 8 h, whereas a slower release occurred from the
moulds. In both the paste and mould formulations a sustained release profile was observed
after 24 h and up to 2 months, and for the paste ~70% of DOX was released after one month.
These release profiles are appropriate for drug therapies required in GBM patients after
surgical resection of primary tumours and warrant translational assessment using human
orthotopic xenograft models for post-surgical drug delivery.
Supplementary Materials: The following are available online at https://www.mdpi.com/1999-492
3/13/2/208/s1, Figure S1. Effect of culture time and seeding density on PrestoBlue fluorescence;
Table S1. NP size and zeta potentials.
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